Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XenoPort has announced the positive results from a double-blind, placebo-controlled, single-dose Phase I clinical trial of XP21279, a transported prodrug L-Dopa for the treatment of Parkinson's disease.
Subscribe to our email newsletter
The trial compared the pharmacokinetic (PK) profile of L-Dopa (levodopa) produced by a single oral dose of a prototype, sustained-release tablet of XP21279 to that of a near-equivalent single dose of oral L-Dopa. The trial demonstrated that XP21279 produced a more sustained exposure of L-Dopa compared to oral L-Dopa dosed in the same healthy subjects. XP21279 was well-tolerated in this first trial in humans.
Ronald Barrett, XenoPort’s CEO, said: “We believe that this clinical trial serves as a solid proof of concept for XP21279. We believe that an optimized formulation of XP21279 could provide therapeutic benefits to patients with Parkinson’s disease, particularly in avoiding periods of wearing-off or the return of symptoms that occur during the day with oral L-Dopa therapy.”